Eda Guzdolu
Research Subjects
Eda Guzdolu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Gulhan Demir
KOCAELİ ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ ENSTİTÜSÜ, TIBBİ GENETİK VE MOLEKÜLER BİYOLOJİ ANABİLİM DALI
2 shared publications - Hakan Savli
Department of Medical Genetics, Faculty of Medicine, Kocaeli University, 41001 Kocaeli, Türkiye
2 shared publications - Naci Cine
Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
2 shared publications - Nilüfer Sertdemir
Bir kuruma bağlı değildir
2 shared publications Bilge Dursun
Kocaeli University Faculty of Medicine, Department of Medical Genetics, Kocaeli, Turkey
1 shared publicationDeniz Sunnetci-Akkoyunlu
Kocaeli University Faculty of Medicine, Department of Medical Genetics, Kocaeli, Turkey
1 shared publication
Latest Publications
- Open Access
- 3 October 2022
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 8 (3) , 172-178
The Mutation Profiles of K-RAS/N-RAS Genes in Metastatic Colorectal Cancer Patients
Objective: RAS genes are members of the RAS/Mitogen activated protein kinase pathway which is induced by Epidermal Growth Factor Receptor (EGFR). Mutations in genes in this pathway trigger cancer development. In colorectal cancer, mutations in RAS genes cause resistance to EGRF- targeted therapy. In the treatment of metastatic colorectal cancer, EGFR’s monoclonal antibodies are widely used as chemotherapeutic agents. Kirsten-RAS mutations are found in 30-50% and N-RAS mutations are found in 2-3% of colorectal cancer. In this study, we aimed to analyze Kirsten-RAS /N-RAS mutations in patients with metastatic colorectal cancer. Methods: One hundred of metastatic colorectal cancer patients resistant to EGFR- targeted therapy were scanned for the Kirsten-RAS mutations status (exon 2,3,4) and N-RAS mutation status (Exon 2,3,4) by Real-Time PCR (Polymerase Chain Reaction) method. Results: As a result of this study, Kirsten-RAS mutation was found 48% and N-RAS mutation was 1.92%. The most common Kirsten-RAS mutations were in codon 12. The distribution of codon 12 mutations were obtained as G12V (25%), G12D (23%), G12C (14.5%). Conclusion: In our study, the frequencies of Kirsten-RAS and N-RAS mutations were compitable with similar reports. Our results have supported that testing RAS genes mutations have a vital role in identifying patients who benefit from Epidermal Growth Factor Receptor- targeted therapy.
- 3 October 2022
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 8 (3) , 172-178
Open AccessThe Mutation Profiles of K-RAS/N-RAS Genes in Metastatic Colorectal Cancer Patients
Objective: RAS genes are members of the RAS/Mitogen activated protein kinase pathway which is induced by Epidermal Growth Factor Receptor (EGFR). Mutations in genes in this pathway trigger cancer development. In colorectal cancer, mutations in RAS genes cause resistance to EGRF- targeted therapy. In the treatment of metastatic colorectal cancer, EGFR’s monoclonal antibodies are widely used as chemotherapeutic agents. Kirsten-RAS mutations are found in 30-50% and N-RAS mutations are found in 2-3% of colorectal cancer. In this study, we aimed to analyze Kirsten-RAS /N-RAS mutations in patients with metastatic colorectal cancer. Methods: One hundred of metastatic colorectal cancer patients resistant to EGFR- targeted therapy were scanned for the Kirsten-RAS mutations status (exon 2,3,4) and N-RAS mutation status (Exon 2,3,4) by Real-Time PCR (Polymerase Chain Reaction) method. Results: As a result of this study, Kirsten-RAS mutation was found 48% and N-RAS mutation was 1.92%. The most common Kirsten-RAS mutations were in codon 12. The distribution of codon 12 mutations were obtained as G12V (25%), G12D (23%), G12C (14.5%). Conclusion: In our study, the frequencies of Kirsten-RAS and N-RAS mutations were compitable with similar reports. Our results have supported that testing RAS genes mutations have a vital role in identifying patients who benefit from Epidermal Growth Factor Receptor- targeted therapy.
- 1 July 2019
- Published by Elsevier in Journal of Biotechnology
- Vol. 300, 87-93
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing
- 1 July 2019
- Published by Elsevier in Journal of Biotechnology
- Vol. 300, 87-93
TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing